img
Science
Science
Science

Clinical development

Our objective is the development of pharmaceutical specialties aimed at treating the major respiratory allergies.

Going beyond our current areas of expertise, we are investigating the therapeutic potential of new clinical indications and demonstrate further evidence of Stallergenes Greer AIT treatments beyond clinical trials.

Clinical trials

Stallergenes Greer’s treatments are supported by many clinical studies to evaluate their safety and efficacy, and to produce high-quality data for decision-making. 

  • Staloral®: More 30 randomized , controlled clinical trials with more than 3,000 patients enrolled in total. The studies aimed to evaluate the tolerability and efficacy of Staloral® for the treatment of allergic rhinitis with or without asthma in the short- and long-term, as well as after stopping the treatment, in children and adults.
  • Oralair® / AitGrys®: full clinical development; more than 2,500 patients enrolled. The studies evaluated the tolerability and efficacy of Oralair® after one month, in the short- and long-term and after stopping the treatment.
  • Actair® / Orylmyte® / Aitmyte® : full clinical development; more than 4,000 patients enrolled. The studies evaluated the tolerability and efficacy of Actair® in the short-term as well as one year after stopping the treatment.

Real-world studies

Real-world studies include large patient populations better reflecting patient profiles in real life. Hence, they provide useful data to optimise AIT prescription and clinical performance. Among the real-world studies conducted by the Group, the most recent ones are:

  • BREATH: evaluated the long-term real-world benefits of AIT in patients with pollen-induced respiratory allergies, based on changes in allergic rhinitis and asthma1,2.
  • EfficAPSI: the largest retrospective real-world, longitudinal cohort study of liquid sublingual AIT. Its objective was to evaluate the real-life impact of liquid sublingual AIT on asthma onset and worsening in patients with allergic rhinitis, with or without pre-existing asthma. The study compared more than 100,000 patients treated with liquid sublingual AIT with more than 330,000 patients receiving symptomatic drugs only, using French nationwide healthcare data3,4.
  • MaDo: a retrospective real-world study involving specialists in France, exploring how and why liquid sublingual AIT doses were adjusted in clinical practice and assessing the impact of these adjustments on treatment effectiveness and tolerability5.
  • PRACTIS: a prospective, multicentre real-world study involving more than 1,500 patients in France, evaluating the use and benefits of sublingual AIT in current practice according to treatment modalities and allergen types, as well as patient involvement, adherence and satisfaction6.
  • CORAP: a French cross-sectional patient survey among adult allergic patients treated with SLIT before and during the COVID-19 pandemic, evaluating patients’ perception of COVID-19-related risk, the impact on allergy symptoms and SLIT management, and attitudes toward COVID-19 infection and vaccination7.

 

 

 

 

  1. Devillier P, et al. Expert Rev Clin Immunol. 2017;13:1199–1206.
  2. Zielen S, et al. Allergol Int. 2025;74:572–578.
  3. Demoly P, et al. Lancet Reg Health Eur. 2024;41:100915.
  4. Devillier P, et al. J Investig Allergol Clin Immunol. 2025. doi:10.18176/jiaci.1142.
  5. Thétis-Soulié M, et al. Front Allergy. 2022;3:971155.
  6. Chabane H, et al. J Allergy Hypersens Dis. 2026;9:100063.
  7. Devillier P, et al. World Allergy Organ J. 2024;17:100902.